Principia Biopharma Inc. (PRNB): IPOs News

PRNB – Company has priced 6.3M shares at $17.00.

Key Facts Surrounding This News Item

  • PRNB had returned 0.00% year-to-date leading up to today’s news, versus a +9.26% return from the benchmark S&P 500 during the same period.

More Info About Principia Biopharma Inc. (PRNB)

Principia Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has collaboration agreements with Genzyme Corporation and AbbVie Biotechnology Limited. Principia Biopharma Inc. was founded in 2008 and is based in South San Francisco, California. View our full PRNB ticker page with ratings, news, and more.

PRNB at a Glance

PRNB Current POWR Rating™
Overall POWR Rating™
PRNB Current Price $32.08 0.56%
More PRNB Ratings, Data, and News

PRNB Price Reaction

The day of this event (Sep. 13, 2018)
PRNB Closing Price0.00 N/A%
PRNB Volume0
N/A% from avg
Leading up to this event
PRNB 1-mo returnN/A%

PRNB Price Chart

The Top Stocks For 2019

More Principia Biopharma Inc. (PRNB) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All PRNB News
Page generated in 0.6783 seconds.